-
Iran executes two more members of exiled opposition: group
-
Pope Leo visits Angola's diamond-rich northeast
-
US begins 'biggest ever' Philippines war games in thick of Mideast conflict
-
Bulgaria ex-president wins parliamentary majority
-
Oil prices jump on Iran war escalation but stocks up on peace hope
-
US begins 'biggest ever' Philippines war games in thick of Mideast war
-
Anxiety lingers in divided Kashmir a year after shooting attack
-
Hit reality show helps rev up Japan's delinquent youth subculture
-
Magic shock Pistons as Thunder and Celtics win big in NBA playoffs
-
Oil prices bounce back on Iran war escalation
-
Residents return to ravaged homes months after Hong Kong fire
-
Australia's Green wins playoff for third LPGA LA Championship title
-
Pakistan's military chief takes lead on US-Iran talks in diplomatic blitz
-
Thunder, Celtics open NBA playoffs with big wins, Magic shock Pistons
-
US begins Philippines war games in thick of Middle East conflict
-
Who's Bad? Not Michael Jackson in new big-budget biopic
-
Nations gather for first-ever conference on fossil fuel exit
-
Money, lobbyists, inertia: why fossil fuels are so hard to quit
-
France summons Elon Musk over X probe
-
'Save humanity': Four figures battling it out to lead embattled UN
-
Gilgeous-Alexander, Wemby, Jokic finalists for NBA MVP
-
Israel vows to level homes in Lebanon, counter threats with 'full force'
-
Rahm coasts to LIV Golf win in Mexico City
-
Fitzpatrick survives Scheffler playoff to win RBC Heritage
-
Thunder thrash Suns, Celtics crush Sixers in NBA playoff openers
-
Bulgaria's former president tops parliamentary vote
-
Kenyans Korir, Lokedi seek to repeat at Boston Marathon
-
AC Milan, Juventus close in on Champions League qualification
-
Spring double keeps Racing 92 in Top 14 play-off hunt with Paris derby win
-
Endrick stars as Lyon dent PSG's Ligue 1 title hopes
-
History haunts Arsenal as Man City take control of title race
-
AC Milan and Juventus close in on Champions League qualification
-
Iran not planning to attend talks with US in Pakistan
-
Celtics crush Sixers as Tatum and Brown shine in playoff opener
-
Guardiola warns title not won yet as Man City hunt down Arsenal
-
Arteta tells Arsenal to 'go again' in pursuit of Premier League title
-
Treble-chasing Bayern put beer showers on ice despite title win
-
Eight children dead in US domestic violence shooting
-
Arya, Connolly help Punjab hammer Lucknow in IPL
-
Man City beat Arsenal to seize control of title race, Liverpool win
-
Kane scores as Bayern sink Stuttgart to claim Bundesliga title
-
Balogun continues Monaco scoring streak, Rennes boost Champions League hopes
-
Trump orders negotiators to Pakistan, but Iran on the fence over talks
-
Haaland gives Man City edge over Arsenal in Premier League title showdown
-
Slot hails Liverpool mentality after last-gasp derby winner
-
Top boss vows 'no sitting still' as rugby bids to conquer US
-
Fils wins on Barcelona clay with French Open looming
-
'Super Mario Galaxy' rules N. America box office for third week
-
Liverpool snatch derby win ahead of City-Arsenal showdown
-
Evenepoel outsprints Skjelmose to win Amstel Gold Race
The scientist rewriting DNA, and the future of medicine
A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose pioneering work is rewriting the building blocks of life with unprecedented precision.
A professor at the Broad Institute of MIT and Harvard, Liu was awarded a Breakthrough Prize in Life Sciences on Saturday for developing two transformative technologies: one already improving the lives of patients with severe genetic diseases, the other poised to reshape medicine in the years ahead.
He spoke with AFP ahead of the Los Angeles ceremony for the prestigious Silicon Valley-founded award.
He will receive $3 million for his work on "base editing" and "prime editing," and plans to donate most of it to support his charitable foundation.
"The ability to change a DNA sequence of our choosing into a new sequence of our choosing is a fundamentally very powerful capability," the 51-year-old said, foreseeing uses not just in human medicine but areas like developing more nutritious or disease-resistant crops.
- Correcting the code -
DNA is made up of four chemical "letters" -- the nucleotide bases A, G, T and C. Mutations in this sequence cause thousands of human diseases, yet until recently, gene editing could only fix a limited number of them.
Even CRISPR-Cas9, the groundbreaking technology that earned a Nobel Prize in 2020, has major limitations.
It cuts both strands of the DNA helix, making it most useful to disrupt rather than correct genes, while the process can introduce new errors.
"Being able to use genome editing to treat genetic diseases requires, in most cases, ways to correct a DNA misspelling, not simply to disrupt a gene," Liu said.
That insight led his lab to develop base editing, which uses the Cas9 protein -- disabled so it can no longer cut both DNA strands -- to find a target DNA sequence and another enzyme to convert one letter to another -- for example, C to T or G to A.
Reversing the change -- from T to C or A to G -- was tougher. Liu's team overcame the challenge by engineering entirely new enzymes.
These base editors can now correct about 30 percent of the mutations that cause genetic diseases. The technology is already in at least 14 clinical trials.
In one of them, Beam Therapeutics -- which Liu co-founded -- announced it had treated patients of AATD, a rare genetic disorder affecting the lungs and liver, with a single drug infusion.
While traditional gene therapies often disrupt faulty genes or work around them, base editing repairs the mutation itself.
"This was the first time that humans have corrected a mutation that causes a genetic disease in a patient," Liu said.
- Cystic fibrosis hope -
Base editing, quickly dubbed "CRISPR 2.0," can't fix every mutation.
About 70 percent of the roughly 100,000 known disease-causing mutations remain out of its reach, including those caused by missing or extra letters.
To expand the toolkit, Liu's lab introduced prime editing in 2019 -- a method capable of replacing entire sections of faulty DNA with corrected sequences.
If CRISPR is like scissors that cut DNA, and base editors are like using a pencil to correct individual letters, then prime editing is the equivalent of a word processor's "find and replace" function.
Creating this tool required a series of breakthroughs Liu's team describes as "small miracles." The result is, he said, "the most versatile way we know of to edit the human genome."
Among the targets Liu and his team have already pursued with prime editing: cystic fibrosis, a common genetic disease usually caused by three missing DNA letters that causes thick mucus buildup in the lungs and digestive system.
Liu's lab has made much of its work freely accessible, sharing DNA blueprints through a nonprofit library used by tens of thousands of labs worldwide.
"The science we create -- which is ultimately funded by society, through governments and donors -- ultimately goes back to benefit society."
This year's Breakthrough Prize awards come at a fraught moment for US science, as President Donald Trump's government strips funding for institutions like the National Institutes of Health (NIH).
"The NIH is a treasure, not just for this country but for the world," said Liu. "Trying to dismantle the heart of what supports science in this country is like burning your seed corn."
N.AbuHussein--SF-PST